Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

The spectrum of acute cardiopulmonary events associated with multiple sclerosis exacerbations.

Valencia-Sanchez C, Goodman BP, Carter JL, Wingerchuk DM.

Mult Scler. 2019 Jan 18:1352458518823482. doi: 10.1177/1352458518823482. [Epub ahead of print]

PMID:
30657008
2.

Are Postprocedural Blood Pressure Goals Associated With Clinical Outcome After Mechanical Thrombectomy for Acute Ischemic Stroke?

Blech B, Chong BW, Sands KA, Wingerchuk DM, Jackson WT, Marks LA, O'Carroll CB.

Neurologist. 2019 Jan;24(1):44-47. doi: 10.1097/NRL.0000000000000223. Review.

PMID:
30586036
3.

Does High Cerebral Microbleed Burden Increase the Risk of Intracerebral Hemorrhage After Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke?

Arca KN, Demaerschalk BM, Almader-Douglas D, Wingerchuk DM, O'Carroll CB.

Neurologist. 2019 Jan;24(1):40-43. doi: 10.1097/NRL.0000000000000228. Review.

PMID:
30586035
4.

Updated diagnostic criteria for neuromyelitis optica spectrum disorder: Similar outcomes of previously separate cohorts.

McCreary M, Mealy MA, Wingerchuk DM, Levy M, DeSena A, Greenberg BM.

Mult Scler J Exp Transl Clin. 2018 Dec 6;4(4):2055217318815925. doi: 10.1177/2055217318815925. eCollection 2018 Oct-Dec.

5.

Is Patent Foramen Ovale Closure More Effective Than Medical Therapy in Preventing Stroke Recurrence in Patients With Cryptogenic Stroke?: A Critically Appraised Topic.

Valencia-Sanchez C, Fortuin FD, Sweeney JP, Ingall TJ, Marks LA, Wingerchuk DM, O'Carroll CB.

Neurologist. 2018 Sep;23(5):175-180. doi: 10.1097/NRL.0000000000000200. Review.

PMID:
30169372
6.

Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome.

Chen JJ, Flanagan EP, Jitprapaikulsan J, López-Chiriboga ASS, Fryer JP, Leavitt JA, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Tobin WO, Keegan BM, Lucchinetti CF, Kantarci OH, McClelland CM, Lee MS, Bennett JL, Pelak VS, Chen Y, VanStavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Brazis PW, Sagen J, Pittock SJ.

Am J Ophthalmol. 2018 Nov;195:8-15. doi: 10.1016/j.ajo.2018.07.020. Epub 2018 Jul 26.

7.

Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis.

Sechi E, Morris PP, McKeon A, Pittock SJ, Hinson SR, Weinshenker BG, Aksamit AJ, Krecke KN, Kaufmann TJ, Jolliffe EA, Zalewski NL, Zekeridou A, Wingerchuk DM, Jitprapaikulsan J, Flanagan EP.

J Neurol Neurosurg Psychiatry. 2018 Jul 21. pii: jnnp-2018-318004. doi: 10.1136/jnnp-2018-318004. [Epub ahead of print] No abstract available.

PMID:
30032117
8.

Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders.

López-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP, Jitprapaikulsan J, Kothapalli N, Tillema JM, Chen J, Weinshenker B, Wingerchuk D, Sagen J, Gadoth A, Lennon VA, Keegan BM, Lucchinetti C, Pittock SJ.

JAMA Neurol. 2018 Nov 1;75(11):1355-1363. doi: 10.1001/jamaneurol.2018.1814.

PMID:
30014148
9.

Is Adjunctive Progesterone Effective in Reducing Seizure Frequency in Patients With Intractable Catamenial Epilepsy? A Critically Appraised Topic.

Valencia-Sanchez C, Crepeau AZ, Hoerth MT, Butler KA, Almader-Douglas D, Wingerchuk DM, O'Carroll CB.

Neurologist. 2018 May;23(3):108-112. doi: 10.1097/NRL.0000000000000167.

PMID:
29722747
10.

Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS.

Corboy JR, Weinshenker BG, Wingerchuk DM.

Neurology. 2018 Jun 12;90(24):1106-1112. doi: 10.1212/WNL.0000000000005574. Epub 2018 Apr 23. Review.

PMID:
29685920
11.

Immune-Mediated Myelopathies.

Wingerchuk DM.

Continuum (Minneap Minn). 2018 Apr;24(2, Spinal Cord Disorders):497-522. doi: 10.1212/CON.0000000000000582.

PMID:
29613897
12.

Acute Basilar Artery Occlusion: Does Recanalization Improve Clinical Outcome? A Critically Appraised Topic.

Chiang CC, Dumitrascu OM, Wingerchuk DM, O'Carroll CB.

Neurologist. 2018 Mar;23(2):71-74. doi: 10.1097/NRL.0000000000000156. Review.

PMID:
29494441
13.

What is Clinical Efficacy of Transesophageal Echocardiography in Patients With Cryptogenic Stroke?: A Critically Appraised Topic.

Christiansen ME, Van Woerkom RC, Demaerschalk BM, Wingerchuk DM, O'Carroll CB.

Neurologist. 2018 Jan;23(1):30-33. doi: 10.1097/NRL.0000000000000155.

PMID:
29266043
14.

NEDA treatment target? No evident disease activity as an actionable outcome in practice.

Parks NE, Flanagan EP, Lucchinetti CF, Wingerchuk DM.

J Neurol Sci. 2017 Dec 15;383:31-34. doi: 10.1016/j.jns.2017.10.015. Epub 2017 Oct 13. Review.

PMID:
29246616
15.

High risk of postpartum relapses in neuromyelitis optica spectrum disorder.

Klawiter EC, Bove R, Elsone L, Alvarez E, Borisow N, Cortez M, Mateen F, Mealy MA, Sorum J, Mutch K, Tobyne SM, Ruprecht K, Buckle G, Levy M, Wingerchuk D, Paul F, Cross AH, Jacobs A, Chitnis T, Weinshenker B.

Neurology. 2017 Nov 28;89(22):2238-2244. doi: 10.1212/WNL.0000000000004681. Epub 2017 Nov 1.

16.

Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders.

Mealy MA, Kim SH, Schmidt F, López R, Jimenez Arango JA, Paul F, Wingerchuk DM, Greenberg BM, Kim HJ, Levy M.

Mult Scler. 2018 Nov;24(13):1737-1742. doi: 10.1177/1352458517730131. Epub 2017 Aug 31.

PMID:
28857723
17.

Author response: Transient smartphone blindness: Relevance to misdiagnosis in neurologic practice.

Wingerchuk DM, Sathiamoorthi S.

Neurology. 2017 Jul 18;89(3):306-307. doi: 10.1212/WNL.0000000000004131. No abstract available.

PMID:
28716876
18.

Is Intravenous Thrombolysis Safe and Effective in Central Retinal Artery Occlusion? A Critically Appraised Topic.

Dumitrascu OM, Shen JF, Kurli M, Aguilar MI, Marks LA, Demaerschalk BM, Wingerchuk DM, O'Carroll CB.

Neurologist. 2017 Jul;22(4):153-156. doi: 10.1097/NRL.0000000000000129. Review.

PMID:
28644261
19.

Predictive models in the diagnosis and treatment of autoimmune epilepsy.

Dubey D, Singh J, Britton JW, Pittock SJ, Flanagan EP, Lennon VA, Tillema JM, Wirrell E, Shin C, So E, Cascino GD, Wingerchuk DM, Hoerth MT, Shih JJ, Nickels KC, McKeon A.

Epilepsia. 2017 Jul;58(7):1181-1189. doi: 10.1111/epi.13797. Epub 2017 May 26.

20.

Neuromyelitis Spectrum Disorders.

Weinshenker BG, Wingerchuk DM.

Mayo Clin Proc. 2017 Apr;92(4):663-679. doi: 10.1016/j.mayocp.2016.12.014. Review.

PMID:
28385199
21.

Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study.

Bove R, Elsone L, Alvarez E, Borisow N, Cortez MM, Mateen FJ, Mealy MA, Mutch K, Tobyne S, Ruprecht K, Buckle G, Levy M, Wingerchuk DM, Paul F, Cross AH, Weinshenker B, Jacob A, Klawiter EC, Chitnis T.

Neurol Neuroimmunol Neuroinflamm. 2017 Mar 24;4(3):e339. doi: 10.1212/NXI.0000000000000339. eCollection 2017 May.

22.

Transient smartphone blindness: Relevance to misdiagnosis in neurologic practice.

Sathiamoorthi S, Wingerchuk DM.

Neurology. 2017 Feb 21;88(8):809-810. doi: 10.1212/WNL.0000000000003639. Epub 2017 Jan 18. No abstract available.

PMID:
28100724
23.

Neuromyelitis optica spectrum disorder diagnostic criteria: Sensitivity and specificity are both important.

Wingerchuk DM, Weinshenker BG.

Mult Scler. 2017 Feb;23(2):182-184. doi: 10.1177/1352458516688352. Epub 2017 Jan 12. No abstract available.

PMID:
28080211
24.

Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders.

Zalewski NL, Morris PP, Weinshenker BG, Lucchinetti CF, Guo Y, Pittock SJ, Krecke KN, Kaufmann TJ, Wingerchuk DM, Kumar N, Flanagan EP.

J Neurol Neurosurg Psychiatry. 2017 Mar;88(3):218-225. doi: 10.1136/jnnp-2016-314738. Epub 2016 Dec 2.

PMID:
27913626
25.

The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.

Solomon AJ, Bourdette DN, Cross AH, Applebee A, Skidd PM, Howard DB, Spain RI, Cameron MH, Kim E, Mass MK, Yadav V, Whitham RH, Longbrake EE, Naismith RT, Wu GF, Parks BJ, Wingerchuk DM, Rabin BL, Toledano M, Tobin WO, Kantarci OH, Carter JL, Keegan BM, Weinshenker BG.

Neurology. 2016 Sep 27;87(13):1393-9. doi: 10.1212/WNL.0000000000003152. Epub 2016 Aug 31.

26.

Disease modifying therapies for relapsing multiple sclerosis.

Wingerchuk DM, Weinshenker BG.

BMJ. 2016 Aug 22;354:i3518. doi: 10.1136/bmj.i3518. Review.

PMID:
27549763
27.

Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum.

Flanagan EP, Cabre P, Weinshenker BG, Sauver JS, Jacobson DJ, Majed M, Lennon VA, Lucchinetti CF, McKeon A, Matiello M, Kale N, Wingerchuk DM, Mandrekar J, Sagen JA, Fryer JP, Robinson AB, Pittock SJ.

Ann Neurol. 2016 May;79(5):775-783. doi: 10.1002/ana.24617. Epub 2016 Apr 4.

28.

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Tan CT, Mao Z, Qiu W, Hu X, Wingerchuk DM, Weinshenker BG.

Neurology. 2016 Feb 2;86(5):491-2. doi: 10.1212/WNL.0000000000002366. No abstract available.

PMID:
26833940
29.

Placebo-controlled study in neuromyelitis optica-Ethical and design considerations.

Cree BA, Bennett JL, Sheehan M, Cohen J, Hartung HP, Aktas O, Kim HJ, Paul F, Pittock S, Weinshenker B, Wingerchuk D, Fujihara K, Cutter G, Patra K, Flor A, Barron G, Madani S, Ratchford JN, Katz E.

Mult Scler. 2016 Jun;22(7):862-72. doi: 10.1177/1352458515620934. Epub 2015 Dec 14.

30.

Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.

Voskuhl RR, Wang H, Wu TC, Sicotte NL, Nakamura K, Kurth F, Itoh N, Bardens J, Bernard JT, Corboy JR, Cross AH, Dhib-Jalbut S, Ford CC, Frohman EM, Giesser B, Jacobs D, Kasper LH, Lynch S, Parry G, Racke MK, Reder AT, Rose J, Wingerchuk DM, MacKenzie-Graham AJ, Arnold DL, Tseng CH, Elashoff R.

Lancet Neurol. 2016 Jan;15(1):35-46. doi: 10.1016/S1474-4422(15)00322-1. Epub 2015 Nov 29.

PMID:
26621682
31.

Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.

Juryńczyk M, Weinshenker B, Akman-Demir G, Asgari N, Barnes D, Boggild M, Chaudhuri A, D'hooghe M, Evangelou N, Geraldes R, Illes Z, Jacob A, Kim HJ, Kleiter I, Levy M, Marignier R, McGuigan C, Murray K, Nakashima I, Pandit L, Paul F, Pittock S, Selmaj K, de Sèze J, Siva A, Tanasescu R, Vukusic S, Wingerchuk D, Wren D, Leite I, Palace J.

J Neurol. 2016 Jan;263(1):140-9. doi: 10.1007/s00415-015-7952-8. Epub 2015 Nov 3.

32.

Update on biomarkers in neuromyelitis optica.

Melamed E, Levy M, Waters PJ, Sato DK, Bennett JL, John GR, Hooper DC, Saiz A, Bar-Or A, Kim HJ, Pandit L, Leite MI, Asgari N, Kissani N, Hintzen R, Marignier R, Jarius S, Marcelletti J, Smith TJ, Yeaman MR, Han MH, Aktas O, Apiwattanakul M, Banwell B, Bichuetti D, Broadley S, Cabre P, Chitnis T, De Seze J, Fujihara K, Greenberg B, Hellwig K, Iorio R, Jarius S, Klawiter E, Kleiter I, Lana-Peixoto M, Nakashima, O'Connor K, Palace J, Paul F, Prayoonwiwat N, Ruprecht K, Stuve O, Tedder T, Tenembaum S, Garrahan JP, Aires B, van Herle K, van Pelt D, Villoslada P, Waubant E, Weinshenker B, Wingerchuk D, Würfel J, Zamvil S.

Neurol Neuroimmunol Neuroinflamm. 2015 Jul 23;2(4):e134. doi: 10.1212/NXI.0000000000000134. eCollection 2015 Aug. Review.

33.

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG; International Panel for NMO Diagnosis.

Neurology. 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729. Epub 2015 Jun 19.

34.

Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder.

Kremer S, Renard F, Achard S, Lana-Peixoto MA, Palace J, Asgari N, Klawiter EC, Tenembaum SN, Banwell B, Greenberg BM, Bennett JL, Levy M, Villoslada P, Saiz A, Fujihara K, Chan KH, Schippling S, Paul F, Kim HJ, de Seze J, Wuerfel JT; Guthy-Jackson Charitable Foundation (GJCF) Neuromyelitis Optica (NMO) International Clinical Consortium and Biorepository, Cabre P, Marignier R, Tedder T, van Pelt D, Broadley S, Chitnis T, Wingerchuk D, Pandit L, Leite MI, Apiwattanakul M, Kleiter I, Prayoonwiwat N, Han M, Hellwig K, van Herle K, John G, Hooper DC, Nakashima I, Sato D, Yeaman MR, Waubant E, Zamvil S, Stüve O, Aktas O, Smith TJ, Jacob A, O'Connor K.

JAMA Neurol. 2015 Jul;72(7):815-22. doi: 10.1001/jamaneurol.2015.0248. Review.

35.

Autonomic symptom burden is associated with MS-related fatigue and quality of life.

Cortez MM, Nagi Reddy SK, Goodman B, Carter JL, Wingerchuk DM.

Mult Scler Relat Disord. 2015 May;4(3):258-63. doi: 10.1016/j.msard.2015.03.007. Epub 2015 Apr 8.

PMID:
26008943
36.

IVIG Versus PLEX in the Treatment of Worsening Myasthenia Gravis: What is the Evidence?: A Critically Appraised Topic.

Dhawan PS, Goodman BP, Harper CM, Bosch PE, Hoffman-Snyder CR, Wellik KE, Wingerchuk DM, Demaerschalk BM.

Neurologist. 2015 May;19(5):145-8. doi: 10.1097/NRL.0000000000000026.

PMID:
25970838
37.

Early versus late antiepileptic drug withdrawal for people with epilepsy in remission.

Strozzi I, Nolan SJ, Sperling MR, Wingerchuk DM, Sirven J.

Cochrane Database Syst Rev. 2015 Feb 11;(2):CD001902. doi: 10.1002/14651858.CD001902.pub2. Review.

PMID:
25922863
38.

Challenges and opportunities in designing clinical trials for neuromyelitis optica.

Weinshenker BG, Barron G, Behne JM, Bennett JL, Chin PS, Cree BA, de Seze J, Flor A, Fujihara K, Greenberg B, Higashi S, Holt W, Khan O, Knappertz V, Levy M, Melia AT, Palace J, Smith TJ, Sormani MP, Van Herle K, VanMeter S, Villoslada P, Walton MK, Wasiewski W, Wingerchuk DM, Yeaman MR; Guthy-Jackson Charitable Foundation International Clinical Consortium.

Neurology. 2015 Apr 28;84(17):1805-15. doi: 10.1212/WNL.0000000000001520. Epub 2015 Apr 3. Review.

39.

Physical activity level and future risk of mild cognitive impairment or dementia: a critically appraised topic.

Schlosser Covell GE, Hoffman-Snyder CR, Wellik KE, Woodruff BK, Geda YE, Caselli RJ, Demaerschalk BM, Wingerchuk DM.

Neurologist. 2015 Feb;19(3):89-91. doi: 10.1097/NRL.0000000000000013.

PMID:
25692517
40.

Amantadine for patients with severe traumatic brain injury: a critically appraised topic.

Spritzer SD, Kinney CL, Condie J, Wellik KE, Hoffman-Snyder CR, Wingerchuk DM, Demaerschalk BM.

Neurologist. 2015 Jan;19(2):61-4. doi: 10.1097/NRL.0000000000000001. Review.

PMID:
25607336
41.

Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions.

Popescu BF, Guo Y, Jentoft ME, Parisi JE, Lennon VA, Pittock SJ, Weinshenker BG, Wingerchuk DM, Giannini C, Metz I, Brück W, Shuster EA, Carter J, Boyd CD, Clardy SL, Cohen BA, Lucchinetti CF.

Neurology. 2015 Jan 13;84(2):148-58. doi: 10.1212/WNL.0000000000001126. Epub 2014 Dec 10.

42.

Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.

Flanagan EP, Weinshenker BG, Krecke KN, Lennon VA, Lucchinetti CF, McKeon A, Wingerchuk DM, Shuster EA, Jiao Y, Horta ES, Pittock SJ.

JAMA Neurol. 2015 Jan;72(1):81-7. doi: 10.1001/jamaneurol.2014.2137.

43.

AQP4 autoantibody assay performance in clinical laboratory service.

Fryer JP, Lennon VA, Pittock SJ, Jenkins SM, Fallier-Becker P, Clardy SL, Horta E, Jedynak EA, Lucchinetti CF, Shuster EA, Weinshenker BG, Wingerchuk DM, McKeon A.

Neurol Neuroimmunol Neuroinflamm. 2014 May 22;1(1):e11. doi: 10.1212/NXI.0000000000000011. eCollection 2014 Jun.

44.

Evaluation of aquaporin-4 antibody assays.

Waters PJ, Pittock SJ, Bennett JL, Jarius S, Weinshenker BG, Wingerchuk DM.

Clin Exp Neuroimmunol. 2014 Oct;5(3):290-303. Epub 2014 Apr 22.

45.

Active and progressive: a new duality of MS classification.

Cross AH, Wingerchuk DM, Weinshenker BG.

Neurology. 2014 Jul 15;83(3):206-7. doi: 10.1212/WNL.0000000000000601. Epub 2014 Jun 13. No abstract available.

PMID:
24928117
46.

Neuromyelitis optica (Devic's syndrome).

Wingerchuk DM, Weinshenker BG.

Handb Clin Neurol. 2014;122:581-99. doi: 10.1016/B978-0-444-52001-2.00025-X. Review.

PMID:
24507536
47.

Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.

Wingerchuk DM, Carter JL.

Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002. Review.

PMID:
24485135
48.

Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.

Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M.

JAMA Neurol. 2014 Mar;71(3):324-30. doi: 10.1001/jamaneurol.2013.5699.

PMID:
24445513
49.

The two faces of neuromyelitis optica.

Weinshenker BG, Wingerchuk DM.

Neurology. 2014 Feb 11;82(6):466-7. doi: 10.1212/WNL.0000000000000114. Epub 2014 Jan 10. No abstract available.

PMID:
24415570
50.

Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis.

Thaera GM, Wingerchuk DM, Carter JL.

Mult Scler Relat Disord. 2014 Jan;3(1):107-9. doi: 10.1016/j.msard.2013.05.003. Epub 2013 Jun 15.

PMID:
25877980

Supplemental Content

Loading ...
Support Center